Insulin aspart

Insulin aspart
Systematic (IUPAC) name
?
Identifiers
CAS number	116094-23-6
ATC code	A10AB05
PubChem	16132418
Chemical data
Formula	C256H387N65O79S6
Mol. mass	5831.6 g/mol
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?

WikiDoc Resources for Insulin aspart
Articles
Most recent articles on Insulin aspart Most cited articles on Insulin aspart Review articles on Insulin aspart Articles on Insulin aspart in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Insulin aspart Images of Insulin aspart Photos of Insulin aspart Podcasts & MP3s on Insulin aspart Videos on Insulin aspart
Evidence Based Medicine
Cochrane Collaboration on Insulin aspart Bandolier on Insulin aspart TRIP on Insulin aspart
Clinical Trials
Ongoing Trials on Insulin aspart at Clinical Trials.gov Trial results on Insulin aspart Clinical Trials on Insulin aspart at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Insulin aspart NICE Guidance on Insulin aspart NHS PRODIGY Guidance FDA on Insulin aspart CDC on Insulin aspart
Books
Books on Insulin aspart
News
Insulin aspart in the news Be alerted to news on Insulin aspart News trends on Insulin aspart
Commentary
Blogs on Insulin aspart
Definitions
Definitions of Insulin aspart
Patient Resources / Community
Patient resources on Insulin aspart Discussion groups on Insulin aspart Patient Handouts on Insulin aspart Directions to Hospitals Treating Insulin aspart Risk calculators and risk factors for Insulin aspart
Healthcare Provider Resources
Symptoms of Insulin aspart Causes & Risk Factors for Insulin aspart Diagnostic studies for Insulin aspart Treatment of Insulin aspart
Continuing Medical Education (CME)
CME Programs on Insulin aspart
International
Insulin aspart en Espanol Insulin aspart en Francais
Business
Insulin aspart in the Marketplace Patents on Insulin aspart
Experimental / Informatics
List of terms related to Insulin aspart

Overview

Insulin aspart (marketed by Novo Nordisk as "NovoLog®/NovoRapid") is a fast acting insulin analogue. It was created through recombinant DNA technology so that the amino acid, B28, which is normally proline, is substituted with an aspartic acid residue. The sequence was inserted into the yeast genome, and the yeast expressed the insulin analogue, which was then harvested from a bioreactor. This analogue also prevents the formation of hexamers, to create a faster acting insulin. Can be used in CSII pumps and Flexpen, Novopen delivery devices for subcutaneous injection.

According to JDRF, insulin aspart was approved for marketing in the United States by the Food and Drug Administration in June of 2000.

It has been debated whether or not insulin aspart (or NovoLog®/NovoRapid) should be refrigerated. Recent studies have shown that there is no difference, however insulin should not be stored in intense heat for a long period of time. This causes the hormone to reach a pre- boiling state, and separate. This can change the potency of the insulin, and it would no longer be as effective. A good rule of thumb is to keep the insulin at around room temperature or less.